NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-Lymphocyte Responses in Patients with Myelodysplastic Syndrome.

CONCLUSION: These data indicate that vaccination against induced NY-ESO-1 expression can produce an antigen-specific immune response in a relatively non-immunogenic myeloid cancer and highlight the potential for induced-antigen directed immunotherapy in a group of patients with limited options. PMID: 28947565 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28947565?dopt=Abstract

Source: Clinical Cancer Research - September 25, 2017 Category: Cancer & Oncology Authors: Griffiths EA, Srivastava P, Matsuzaki J, Brumberger Z, Wang ES, Kocent J, Miller A, Roloff GW, Wong HY, Paluch BE, Lutgen-Dunckley LG, Martens BL, Odunsi K, Karpf AR, Hourigan CS, Nemeth MJ Tags: Clin Cancer Res Source Type: research